Table 1 Examples of drugs targeting tyrosine kinases receptors that are being tested in different clinical trials
TARGET | DRUG | DISEASE | TRIAL PHASE | STATUS | CLINICAL TRIAL NUMBER |
|---|---|---|---|---|---|
MET | Tivantinib | Advanced/Recurrent Gastric Cancer | II | Completed | NCT01152645 |
MET/EGFR/Topoisomerase | Tivantinib + cetuximab + irinotecan | Metastatic Colon Cancer | I/II | Completed | NCT01075048 |
MET/EGFR | Tivantinib + erlotinib | NSCLC | III | Completed | NCT01244191 |
MET/EGFR | Tivantinib + erlotinib | Locally Advanced or Metastatic NSCLC | II | Completed | NCT01395758 |
MET/Thymidylate Synthase | Tivantinib + FOLFOX | Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | I | Completed | NCT01611857 |
MET | Tivantinib | Metastatic Breast Cancer | II | Completed | NCT01575522 |
EGFR | Erlotinib | Bladder Cancer | II | Completed | NCT00380029 |
EGFR | Erlotinib | Advanced Head and Neck Cancer | II | Terminated | NCT00750555 |
EGFR | Gefitinib | Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer | II | Completed | NCT00268346 |
EGFR | Gefitinib | Advanced or Metastatic Thyroid Cancer | II | Completed | NCT00095836 |
EGFR | Afatinib | Hormone-Refractory Prostate Cancer | II | Completed | NCT01320280 |
EGFR | Afatinib | Breast Cancer | II | Completed | NCT01325428 |
EGFR | Afatinib | Head and Neck Cancer | III | Terminated | NCT01345669 |
EGFR | Rociletinib or Erlotinib | Metastatic NSCLC | II | Terminated | NCT02186301 |
EGFR | Lapatinib + Ciscplatin + Radiotherapy | Head and Neck Cancer | II | Terminated | NCT00387127 |
PDGFR/Microtubule | Dasatinib + Ixabepilone | Metastatic Breast Cancer | I | Completed | NCT00924352 |
PDGFR/Microtubule | Dasatinib + Docetaxel | Metastatic Hormone-Refractory Prostate Cancer | II | Completed | NCT00439270 |
PDGFR/EGFR | Dasatinib + Erlotinib | NSCLC | II | Completed | NCT00826449 |
Multiple Receptor Tyrosine Kinases (PDGFR, c-KIT, VEGFRs) | Sunitinib | Pancreatic Neuroendocrine Tumors | III | Terminated | NCT00428597 |
Multiple Receptor Tyrosine Kinases (PDGFR, c-KIT, VEGFRs) | Sunitinib | Esophageal Cancer | II | Completed | NCT00702884 |
Multiple Receptor Tyrosine Kinases (PDGFR, c-KIT, VEGFRs)/Microtubule/EGFR | Sunitinib + Docetaxel + Trastuzumab | Advanced Breast Cancer | I | Completed | NCT00372424 |
ALK | Ceritinib | Tumors Characterized by Genetic Abnormalities in ALK | I | Completed | NCT01283516 |
MET and VEGFR | Cabozantinib | Prostate Cancer | II | Completed | NCT01834651 |
VEGFR/Microtubule | Bevacizumab + Paclitaxel | Metastatic Breast Cancer (HER-2 negative) | II | Active | NCT01663727 |